Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma
10.4068/cmj.2015.51.3.109
- Author:
Deok Hwan YANG
1
;
Sung Hoon JUNG
;
Jae Sook AHN
;
Yeo Kyeoung KIM
;
Jung Joon MIN
;
Hee Seung BOM
;
Je Jung LEE
;
Hyeoung Joon KIM
Author Information
1. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea. drydh1685@hotmail.com
- Publication Type:Review
- Keywords:
Prognosis;
Lymphoma;
Non-Hodgkin;
Positron-emission tomography
- MeSH:
Education;
Electrons;
Humans;
Induction Chemotherapy;
Lymphoma;
Lymphoma, Non-Hodgkin;
Observer Variation;
Positron-Emission Tomography;
Positron-Emission Tomography and Computed Tomography;
Prognosis
- From:Chonnam Medical Journal
2015;51(3):109-114
- CountryRepublic of Korea
- Language:English
-
Abstract:
The prognostic value of whole-body positron emission tomography/computed tomography (PET/CT) with 18F-fluoro-2-deoxy-D-glucose (FDG) shortly after the onset of induction chemotherapy or mid treatment could help to predict long-term clinical outcomes in patients with Hodgkin's or Non-Hodgkin's lymphoma. However, FDG is not a tumor-specific substance, and it may accumulate to the point of being detected in a variety of benign conditions or at physiologic anatomical sites, which may give rise to false-positive interpretation. In an attempt to standardize the reporting criteria for interim PET/CT, the First International Workshop on Interim PET in Lymphoma suggested visual response criteria with the Deauville five-point scale, and the standardized uptake value (SUV) has been investigated in comparison with this visual system. A quantitative approach using the measurement of maximal SUV (SUVmax) or the reduction rate of SUVmax (DeltaSUVmax) might be more appropriate in early-response PET/CT for reducing false-positive rates or for decreasing interobserver variability in interpretation. In this review, the predictive efficacy of PET/CT is discussed for the treatment of aggressive lymphoma, especially in terms of an interim PET/CT-based prognostic model.
